| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ECP.10.31 |
| P8608 | Fatcat ID | release_gd245qulonf5tp5li27q7zzcfy |
| P698 | PubMed publication ID | 22111681 |
| P2093 | author name string | Jun Oh | |
| Markus J Kemper | |||
| P2860 | cites work | Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations | Q33300551 |
| Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome | Q33625306 | ||
| The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. | Q33943247 | ||
| Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children | Q34659232 | ||
| Eight and 12 week courses of cyclophosphamide in nephrotic syndrome | Q35625194 | ||
| Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome | Q36153584 | ||
| Tacrolimus in the treatment of idiopathic nephrotic syndrome. | Q36861628 | ||
| Evaluation and management of steroid-sensitive nephrotic syndrome | Q37107065 | ||
| Experience with tacrolimus in children with steroid-resistant nephrotic syndrome | Q37229944 | ||
| Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie | Q37315097 | ||
| Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome | Q37330330 | ||
| Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? | Q37507490 | ||
| Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome | Q37682710 | ||
| Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis | Q39342730 | ||
| Management patterns of childhood-onset nephrotic syndrome | Q39956110 | ||
| Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome | Q43284411 | ||
| Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide | Q43784012 | ||
| Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up | Q43935632 | ||
| Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome | Q44458286 | ||
| Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade | Q44481330 | ||
| Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome | Q44679612 | ||
| Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil | Q44749406 | ||
| Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome | Q44752973 | ||
| Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome | Q44782178 | ||
| Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome | Q44795809 | ||
| Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome | Q45122865 | ||
| Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy | Q45126690 | ||
| The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. | Q45270502 | ||
| Switch from cyclosporine A to mycophenolate mofetil in nephrotic children | Q45272404 | ||
| FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy | Q45757311 | ||
| Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. | Q46030055 | ||
| Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases | Q46079811 | ||
| Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial | Q46096920 | ||
| Remission of refractory minimal change nephrotic syndrome after basiliximab therapy | Q46109510 | ||
| Cyclosporin A absorption profiles in children with nephrotic syndrome | Q46459529 | ||
| Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome | Q46486654 | ||
| Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome | Q46488621 | ||
| Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? | Q46506765 | ||
| Vincristine treatment in steroid-dependent nephrotic syndrome | Q46565447 | ||
| Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome | Q46673010 | ||
| Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis | Q46694715 | ||
| Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience | Q46705142 | ||
| Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus | Q46823230 | ||
| Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children | Q46881412 | ||
| Differential risk of remission and ESRD in childhood FSGS. | Q46893726 | ||
| Rituximab for refractory focal segmental glomerulosclerosis | Q46922097 | ||
| Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children | Q47864240 | ||
| Fatal pulmonary fibrosis after rituximab administration | Q47935891 | ||
| Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. | Q51741633 | ||
| Rituximab in refractory nephrotic syndrome. | Q53063316 | ||
| Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. | Q53365410 | ||
| Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome. | Q53996280 | ||
| A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. | Q54047507 | ||
| Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. | Q54465513 | ||
| Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity | Q57691291 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 527-537 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome | |
| P478 | volume | 3 |
| Q53702610 | Calcineurin inhibitors and nephrotoxicity in children. |
| Q40278174 | Cocaine-induced vasculitis: clinical and immunological spectrum |
| Q26781358 | Nonimmunologic targets of immunosuppressive agents in podocytes |
| Q51292313 | Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula. |
| Q39039438 | Vincristine alleviates adriamycin-induced nephropathy through stabilizing actin cytoskeleton |
Search more.